Gabriela Tomescu
Corporate Officer/Principal chez Apneon, Inc.
Postes actifs de Gabriela Tomescu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Apneon, Inc.
 Apneon, Inc. Medical SpecialtiesHealth Technology Founded in 2003 by Dr. Lionel Nelson and Eric Doelling, Apneon is dedicated to developing innovative solutions for treating obstructive sleep apnea (OSA) - the cessation of breathing during sleep. OSA is a serious and life-threatening condition that plagues millions of Americans and is most commonly recognized by excessive daytime sleepiness. Even with current treatments, sleep apnea is associated with significantly increased risk of stroke and death. Current treatment methods tend to be poorly tolerated, and/or of limited efficacy. Apneon is developing a unique and inventive approach intended to provide an effective treatment for OSA. | Corporate Officer/Principal | 01/09/2005 | - |
Historique de carrière de Gabriela Tomescu
Formation de Gabriela Tomescu
| The Ohio State University | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Georgetown University | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Graduate Degree | 2 |
| Undergraduate Degree | 2 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Consumer Services | 4 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Apneon, Inc.
Apneon, Inc. Medical SpecialtiesHealth Technology Founded in 2003 by Dr. Lionel Nelson and Eric Doelling, Apneon is dedicated to developing innovative solutions for treating obstructive sleep apnea (OSA) - the cessation of breathing during sleep. OSA is a serious and life-threatening condition that plagues millions of Americans and is most commonly recognized by excessive daytime sleepiness. Even with current treatments, sleep apnea is associated with significantly increased risk of stroke and death. Current treatment methods tend to be poorly tolerated, and/or of limited efficacy. Apneon is developing a unique and inventive approach intended to provide an effective treatment for OSA. | Health Technology |
- Bourse
- Insiders
- Gabriela Tomescu
- Expérience
